Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
KNAW Bob Pinedo Cancer Care Award 2020 voor Jesús San Miguel Izquierdo
sep 2020 | MM